MeSH D054179 - hereditary angioedemas
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D000081208:Hereditary complement deficiency diseases
0 Companies
0 Drugs
Success rate
D000799:Angioedema
D054179:Â
Hereditary angioedemas
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Icatibant | Icatibant |  | 2019-07-15 |  |  |
| Glenmark Pharmaceuticals | Icatibant | Icatibant |  | 2021-05-21 |  |  |
| Cipla | Icatibant | Icatibant |  | 2020-07-13 |  |  |
| Takeda | Human c1-esterase inhibitor | Cinryze |  | 2011-06-15 |  |  |
| Icatibant | Firazyr |  | 2011-08-25 |  |  | |
| Ecallantide | Kalbitor |  | 2009-12-01 |  |  | |
| Lanadelumab | Takhzyro |  | 2018-11-22 |  |  | |
| Caplin Steriles | Icatibant | Icatibant |  | 2020-10-05 |  |  |
| Accord Healthcare | Icatibant | Icatibant Accord |  | 2021-07-16 |  |  |
| Wilshire Pharmaceuticals | Icatibant | Icatibant |  | 2020-09-01 |  |  |
| BioCryst Pharmaceuticals | Berotralstat | Orladeyo |  | 2021-04-30 | $404.357 M | Q4/23-Q3/24 |
| Fresenius Kabi | Icatibant | Icatibant |  | 2020-06-18 |  |  |
| Jiangsu Hansoh Pharmaceutical Group | Icatibant | Icatibant |  | 2020-03-09 |  |  |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
56%5/9
Phase 2
83%5/6
Phase 3
58%11/19
Approved: 6Overall Success rate: 27%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use